← Leaderboards
M Attal
Dana-Farber Cancer Inst
$1,384,968
Attributed
$1,384,968
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $353.7K · FY2012–15$500K$375K$250K$125K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$1,384,968 · 1
By mechanism
P01$1,384,968 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Kenneth C Anderson$25,995,373
- Benjamin Levine Ebert$26,802,844
- Irene M. Ghobrial$24,445,801
- Herve Avet Loiseau$3,475,894
- Constantine S. Mitsiades$5,369,219
Others in their field
Top investigators on “Angiogenesis”
- David Heimbrook · Leidos Biomedical Research, Inc.$75,067,502
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$59,567,306
- Martin Friedlander · Scripps Research Institute$48,350,175
- Larry Arthur$33,866,306
- Michael Simons · Yale University$30,647,106
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$29,372,588
Research focus
AngiogenesisApoptosisApoptoticAutologousBinding (Molecular Function)Bone MarrowBortezomibCancer GenomicsCaspase-8Caspase-9Cell CommunicationCellsCessation Of LifeClinical ApplicationClinical ResearchClinical TrialsCombined Modality TherapyCytogeneticsCytokineCytolysisCytotoxicityDana-Farber Cancer InstituteDexamethasoneAlbumins
Grant awards (4)
Role of Combination Therapy with Novel Targeted Agents$350,711
P01 · FY2015 · CA · contact PI
Role of Combination Therapy with Novel Targeted Agents$341,145
P01 · FY2014 · CA · contact PI
Role of Combination Therapy with Novel Targeted Agents$339,391
P01 · FY2013 · CA · contact PI
Role of Combination Therapy with Novel Targeted Agents$353,721
P01 · FY2012 · CA · contact PI